This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choy, A. M. Articles by Roden, D. M. Search for Related Content PubMed PubMed Citation Articles by Choy, A. M. Articles by Roden, D. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB POTASSIUM POTASSIUM CHLORIDE QUINIDINE QUINIDINE SULFATE

(Circulation. 1997;96:2149-2154.)
© 1997 American Heart Association, Inc.

Articles

Normalization of Acquired QT Prolongation in Humans by Intravenous Potassium

Anna Maria Choy, MD; Chim C. Lang, MD; Don M. Chomsky, MD; Glenn H. Rayos, MD; John R. Wilson, MD; ; Dan M. Roden, MD

From the Divisions of Clinical Pharmacology and Cardiology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.

Correspondence to Dan M. Roden, MD, Professor of Medicine and Pharmacology, Director, Division of Clinical Pharmacology, Vanderbilt University, 532C Medical Research Bldg I, Nashville, TN 37232-6602. E-mail dan.roden{at}mcmail.vanderbilt.edu

Background QT interval prolongation and dispersion have been implicated in serious arrhythmias in congestive heart failure (CHF) and the congenital and drug-induced long-QT syndromes (LQTS). In a subset of the congenital LQTS, infusion of potassium can correct QT abnormalities, consistent with in vitro increases in outward currents such as I_Kr or I_K1 when extracellular potassium concentration ([K⁺]_o) is increased. Furthermore, increasing [K⁺]_o decreases the potency of I_Kr-blocking drugs in vitro. The purpose of this study was to test the hypothesis that increasing [K⁺]_o corrects QT abnormalities in CHF and in subjects treated with quinidine.

Methods and Results KCl (maximum, 40 mEq) was infused into (1) 12 healthy subjects treated with quinidine sulfate (5 doses of 300 mg/5 h) or placebo and (2) 8 CHF patients and age-matched normal control subjects. Mean [K⁺] increased from 4 to 4.2 mEq/L to 4.7 to 5.2 mEq/L. Potassium infusion significantly reversed QTU_c prolongation, especially in the precordial leads (quinidine, 590±79 to 479±35 [±SD] ms^1/2, P<.001; CHF, 521±110 to 431±47 ms^1/2, P<.05). There was no effect in either control group. Similarly, potassium decreased QTU_c dispersion (quinidine, 210±62 to 130±75 ms^1/2, P<.01; CHF, 132±68 to 84±35 ms^1/2, P=.07) and was without effect in the control subjects. QT morphological abnormalities, including U waves and bifid T waves, were reversed by potassium.

Conclusions Potentially arrhythmogenic QT abnormalities during quinidine treatment and in CHF can be nearly normalized by modest elevation of serum potassium.

Key Words: potassium • quinidine • heart failure

This article has been cited by other articles:

				T. M. Ng, A. M Bell, C. Hong, J. M Hara, D. R Touchette, K. N Danskey, T. T Lindsay, and S. E Puumala Pharmacist Monitoring of QTc Interval-Prolonging Medications in Critically Ill Medical Patients: A Pilot Study Ann. Pharmacother., April 1, 2008; 42(4): 475 - 482. [Abstract] [Full Text] [PDF]

				J. Xiao, X. Luo, H. Lin, Y. Zhang, Y. Lu, N. Wang, Y. Zhang, B. Yang, and Z. Wang MicroRNA miR-133 Represses HERG K+ Channel Expression Contributing to QT Prolongation in Diabetic Hearts J. Biol. Chem., April 27, 2007; 282(17): 12363 - 12367. [Abstract] [Full Text] [PDF]

				S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]

				M. B. Thomsen, P. G.A. Volders, J. D.M. Beekman, J. Matz, and M. A. Vos Beat-to-Beat Variability of Repolarization Determines Proarrhythmic Outcome in Dogs Susceptible to Drug-Induced Torsades de Pointes J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1268 - 1276. [Abstract] [Full Text] [PDF]

				Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]

				Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]

				P. Sturm, S. Wimmers, J. R Schwarz, and C. K Bauer Extracellular potassium effects are conserved within the rat erg K+ channel family J. Physiol., April 15, 2005; 564(2): 329 - 345. [Abstract] [Full Text] [PDF]

				F. M. Mullins, S. Z. Stepanovic, N. B. Gillani, A. L. George Jr, and J. R. Balser Functional interaction between extracellular sodium, potassium and inactivation gating in HERG channels J. Physiol., August 1, 2004; 558(3): 729 - 744. [Abstract] [Full Text] [PDF]

				J. E. Macdonald and A. D. Struthers What is the optimal serum potassium level in cardiovascular patients? J. Am. Coll. Cardiol., January 21, 2004; 43(2): 155 - 161. [Abstract] [Full Text] [PDF]

				S. Kaab, M. Hinterseer, M. Nabauer, and G. Steinbeck Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome--a case-control pilot study using i.v. sotalol Eur. Heart J., April 1, 2003; 24(7): 649 - 657. [Abstract] [Full Text] [PDF]

				H. J. Witchel, J. C. Hancox, D. J. Nutt, and S. Wilson Antipsychotics, HERG and sudden death The British Journal of Psychiatry, February 1, 2003; 182 (2): 171 - 172. [Full Text] [PDF]

				X. H.T. Wehrens, M. A. Vos, P. A. Doevendans, and H. J.J. Wellens Novel Insights in the Congenital Long QT Syndrome Ann Intern Med, December 17, 2002; 137(12): 981 - 992. [Abstract] [Full Text] [PDF]

				F. M. Mullins, S. Z. Stepanovic, R. R. Desai, A. L. George Jr., and J. R. Balser Extracellular Sodium Interacts with the HERG Channel at an Outer Pore Site J. Gen. Physiol., September 30, 2002; 120(4): 517 - 537. [Abstract] [Full Text] [PDF]

				G.-R. Li, C.-P. Lau, A. Ducharme, J.-C. Tardif, and S. Nattel Transmural action potential and ionic current remodeling in ventricles of failing canine hearts Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1031 - H1041. [Abstract] [Full Text] [PDF]

				X. Xu, J. J. Salata, J. Wang, Y. Wu, G.-X. Yan, T. Liu, R. A. Marinchak, and P. R. Kowey Increasing IKs corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H664 - H670. [Abstract] [Full Text] [PDF]

				K J Paavonen, H Swan, K Piippo, L Hokkanen, P Laitinen, M Viitasalo, L Toivonen, and K Kontula Response of the QT interval to mental and physical stress in types LQT1 and LQT2 of the long QT syndrome Heart, July 1, 2001; 86(1): 39 - 44. [Abstract] [Full Text] [PDF]

				K.-M. Yee, S. D. Pringle, and A. D. Struthers Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1800 - 1807. [Abstract] [Full Text] [PDF]

				P. O. Lim, C. A. J. Farquharson, P. Shiels, R. T. Jung, A. D. Struthers, and T. M. MacDonald Adverse Cardiac Effects of Salt With Fludrocortisone in Hypertension Hypertension, March 1, 2001; 37(3): 856 - 861. [Abstract] [Full Text] [PDF]

				A. M. J. Choy, D. Darbar, S. Dell'Orto, and D. M. Roden Exaggerated QT prolongation after cardioversion of atrial fibrillation J. Am. Coll. Cardiol., August 1, 1999; 34(2): 396 - 401. [Abstract] [Full Text] [PDF]

				A. Busjahn, H. Knoblauch, H.-D. Faulhaber, T. Boeckel, M. Rosenthal, R. Uhlmann, M. Hoehe, H. Schuster, and F. C. Luft QT Interval Is Linked to 2 Long-QT Syndrome Loci in Normal Subjects Circulation, June 22, 1999; 99(24): 3161 - 3164. [Abstract] [Full Text] [PDF]

				P. O. Lim, M. Nys, A. A. O. Naas, A. D. Struthers, M. Osbakken, and T. M. MacDonald Irbesartan Reduces QT Dispersion in Hypertensive Individuals Hypertension, February 1, 1999; 33(2): 713 - 718. [Abstract] [Full Text] [PDF]